Compare · PSTV vs SYK
PSTV vs SYK
Side-by-side comparison of PLUS THERAPEUTICS Inc. (PSTV) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PSTV and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 4760.4x PSTV ($26.6M).
- SYK has been more active in the news (9 items in the past 4 weeks vs 7 for PSTV).
- SYK has more recent analyst coverage (25 ratings vs 3 for PSTV).
- Company
- PLUS THERAPEUTICS Inc.
- Stryker Corporation
- Price
- $3.90+8.79%
- $330.59+0.86%
- Market cap
- $26.6M
- $126.81B
- 1M return
- -
- -1.81%
- 1Y return
- -
- -16.24%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 9
- Recent ratings
- 3
- 25
PLUS THERAPEUTICS Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest PSTV
- Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
- SEC Form 10-Q filed by PLUS THERAPEUTICS Inc.
- PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cerenome Reports Second Quarter 2026 Financial Results and Business Update
- Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
- Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
- PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Cerenome Launches as an Integrated CNS Oncology Company
- Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
- Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation